The effect of statin therapy on the formation of arteriovenous fistula stenoses and the rate of reoccurrence of previously treated stenoses

Hemodialysis International

Volumn 17, Issue 4, 2013, Pages 586-593

  Birch, Nathan ^a   Fillaus, Jennifer ^b   Florescu, Marius C ^b  

^a VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Angioplasty; Arteriovenous fistulas; Statins; Stenoses

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; ANGIOPLASTY; ARTERIOVENOUS FISTULA; ARTICLE; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFECT; ETHNICITY; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PRESCRIPTION; QUALITY OF LIFE; RECURRENT DISEASE; RETROSPECTIVE STUDY; STENOSIS; VASCULAR PATENCY;

ANGIOPLASTY; ARTERIOVENOUS FISTULAS; STATINS; STENOSES;

ARTERIOVENOUS FISTULA; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 84884973231     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2012.00762.x     Document Type: Article

References (24)

1. NKF-K/DOQI clinical practice guidelines for vascular access. Am J Kidney Dis. 2006; 48(Suppl 1):S248-S273.
2. NKF-K/DOQI clinical practice guidelines for vascular access. Am J Kidney Dis. 2006; 48(Suppl 1):S176-S247.
3. Righeti M, Ferrario G, Serbelloni P, Milani S, Tomasi L. Some old drugs improve late primary patency rate of native arteriovenous fistulas in hemodialysis patients. Ann Vasc Surg. 2009; 23:491-497.
4. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996; 7:523-535.
5. Egger P. Trends in Medicare Expenditure for Vascular Access. Presented at the Cincinnati Hemodialysis Vascular Access Symposium, March 19, 2004.
6. Rayner HC, Pisoni RL, Bommer J, etal. Mortality and hospitalization in haemodialysis patients in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004; 19:108-120.
7. Woods JD, Port FK. The impact of vascular access for haemodialysis on patient morbidity and mortality. Nephrol Dial Transplant. 1997; 12:657-659.
8. Allon M. Effect of Change in Vascular Access on Hemodialysis Patient Outcomes. End Stage Renal Disease-Vascular Access pages 11-12;2007.
9. Miller PE, Tolwani A, Luscy CP, etal. Predictors of adequacy of arteriovenous fistulas in hemodialysis patients. Kidney Int. 1999; 56:275-280.
10. Lee T, Ullah A, Allon M, etal. Decreased cumulative access survival in arteriovenous fistulas requiring interventions to promote maturation. Clin J Am Soc Nephrol. 2011; 6:575-581.
11. Gradzki R, Dhingra RK, Port FK, Roys E, Weitzel WF, Messana JM. Use of Ace inhibitors is associated with prolonged survival in arteriovenous grafts. Am J Kidney Dis. 2001; 38:1240-1244.
12. Kaufman JS, O'Connor TZ, Zhang JH, etal. Veterans affairs cooperative study group on hemodialysis access graft thrombosis. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol. 2003; 14:2313-2321.
13. Saran R, Dykstra DM, Wolfe RA, Gillespie B Held PJ, Young EW. Dialysis outcomes and practice patterns study. Association between vascular access failure and the use of specific drugs: The dialysis outcomes and practice patterns study (DOPPPS). Am J Kidney Dis. 2002; 40:1255-1263.
14. Yevzlin AS, Conley EL, Sanchez RJ, Young HN, Becker BN. Vascular access outcomes and medication use: A USRDS study. Semin Dial. 2006 (November-December); 19: 535-539.
15. Pisoni R, Barker-Finkel J, Allon M. Statin therapy is not associated with improved vascular access outcomes. Clin J Am soc Nephrol. 2010; 5:1447-1450.
16. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: A cellular and molecular viewpoint. J Am Soc Nephrol. 2006; 17:1112-1127.
17. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int. 2001; 59:407-414.
18. Kumar S, Raftery M, Yaqoob M, Fan SLS. Anti-inflammatory effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis. 2002; 39:1213-1217.
19. Heimbürger O, Stenvinkel P. Statins to treat chronic inflammation in dialysis patients- is this feasible? Perit Dial Int. 2007; 27:254-257.
20. Campese VM, Nadim MK, Epstein M. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol. 2005; 16:S11-S17. doi: 10.1681/ASN.2004110958.
21. Szmitko PE, Fedak PW, Weisel RD, Stewart DJ, Kutryk MJ, Verma S. Endothelial progenitor cells: New hope for a broken heart. Circulation. 2003; 107:3093-3100.
22. Benget F, etal. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360:1395-1407.
23. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: Results of a prospective, randomized, double-blind study. Kidney Int. 1994; 45:1477-1483.
24. Harvey R, Bredenberg CE, Couper L, Himmelfarb J. Aspirin enhances platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Vasc Surg. 1997; 25:689-695.